New Zilver® PTX® Drug-Eluting Stent Study Data Shows Excellent SFA Patency Results at Four Years Four-year data from the Zilver® PTX® Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical presented today at the 2013 Vascular Interventional Advances meeting demonstrates 75 percent primary patency in the superficial femoral artery at four years for patients treated with Cook Medical’s paclitaxel-eluting stent.
Oct. 8, 2013 - Business Wire via Yahoo! Finance